Viridian data lift prospects for thyroid eye disease drug
Source ↗
👁 0
💬 0
Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.
Comments (0)